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The Journal of Immunology
Hypomethylation at the Regulatory T Cell–Specific
Demethylated Region in CD25hi T Cells Is
Decoupled from FOXP3 Expression at the
Inflamed Site in Childhood Arthritis
David Bending,* Anne M. Pesenacker,*,1 Simona Ursu,* Qiong Wu,† Hannah Lom,*
Balathas Thirugnanabalan,* and Lucy R. Wedderburn*
The maintenance of FOXP3 expression in CD25hi regulatory T cells (Tregs) is crucial to the control of inflammation and essential
for successful Treg transfer therapies. Coexpression of CD25 and FOXP3 in combination with a hypomethylated region within the
FOXP3 gene, called the Treg-specific demethylated region (TSDR), is considered the hallmark of stable Tregs. The TSDR is an
epigenetic motif that is important for stable FOXP3 expression and is used as a biomarker to measure Treg lineage commitment.
In this study, we report that, unlike in peripheral blood, CD4+ T cell expression of CD25 and FOXP3 is frequently dissociated at
the inflamed site in patients with juvenile idiopathic arthritis, which led us to question the stability of human Tregs in chronic
inflammatory environments. We describe a novel CD4+CD127loCD25hi human T cell population that exhibits extensive TSDR and
promoter demethylation in the absence of stable FOXP3 expression. This population expresses high levels of CTLA-4 and can
suppress T conventional cell proliferation in vitro. These data collectively suggest that this population may represent a chronically
activated FOXP3lo Treg population. We show that these cells have defects in IL-2 signaling and reduced expression of a deubi-
quitinase important for FOXP3 stability. Clinically, the proportions of these cells within the CD25hi T cell subset are increased in
patients with the more severe courses of disease. Our study demonstrates, therefore, that hypomethylation at the TSDR can be
decoupled from FOXP3 expression in human T cells and that environment-specific breakdown in FOXP3 stability may compro-
mise the resolution of inflammation in juvenile idiopathic arthritis. The Journal of Immunology, 2014, 193: 2699–2708.
R
egulatory T cells (Tregs) play central roles in controlling
the magnitude of the immune response. Since their
identification (1), FOXP3+ Tregs have been intensively
studied, given their critical roles in regulating immune responses.
Before the discovery of FOXP3, high levels of the IL-2 receptor
a-chain, CD25 (2), had been relied upon as a marker of T cells
with regulatory potential. However, CD25 is not unique to Tregs
because T conventional cells (Tcons) upregulate this receptor
upon activation. Early studies of FOXP3 (1, 3, 4) demonstrated
that the highest CD25-expressing cells were also predominantly
FOXP3hi, and therefore Tregs were defined by high coexpression
of CD25 and FOXP3.
A key paradox often encountered in studies of autoimmune disease,
exemplified by childhood arthritis (Juvenile Idiopathic Arthritis [JIA])
(5, 6), is the enrichment of FOXP3+ T cells at the inflamed site. This
raises the question as to why disease persists despite the enhanced
Treg frequency. Several studies have demonstrated that human
Tcons upregulate FOXP3 upon activation (7–9), suggesting that,
theoretically, any observed CD25hiFOXP3hi T cell population could
contain activated Tcons (9), as well as Tregs. Work by several groups
has shown that epigenetic modifications to the FOXP3 promoter (10)
and intronic enhancer (11, 12) can distinguish Tregs from Tcons.
The intronic enhancer region, which has been called the Treg-
specific demethylated region (TSDR), is an excellent discriminator
between Tregs and promiscuous FOXP3-expressing T cells, and it
can be used as a biomarker to quantify Tregs (13). Activated Tcons,
TGF-b–induced Tregs, and naive T cells all display methylation of
this region. TSDR status can therefore distinguish between a CD25hi
FOXP3hi activated Tcon and a fully committed CD25hiFOXP3hi
Treg, and, theoretically, could also be used to identify Tregs that may
have recently lost FOXP3 expression.
The terms Treg, FOXP3, and/or CD25hi are sometimes used
interchangeably; however, to what extent these markers identify
bona fide Tregs at chronically inflamed sites in humans is un-
known, and the temporal dynamics of FOXP3 and/or CD25 ex-
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pression at inflamed sites are poorly understood. Furthermore,
functional studies are often hindered in humans because Tregs
must be isolated through surrogate cell surface marker expression,
for example, CD25 and CD127 (14). We have previously reported
that CD25 and FOXP3 expression are frequently dissociated in the
synovial fluid (SF) of JIA patients (6), raising questions about the
extent and stability of Tregs at the inflamed site. We reveal that
hypomethylation at the TSDR is decoupled from stable FOXP3
expression in a subset of CD25hi T cells. This population repre-
sents a Treg subset that has very low FOXP3 expression, is pro-
portionally increased in the more severe forms of arthritis, and
displays defects in pathways important for Treg homeostasis. Our
data suggest that the presence of TSDR hypomethylation is not
sufficient in itself to ensure FOXP3 expression.
Materials and Methods
Human samples and cells
Blood samples were obtained from 11 healthy adult volunteers and 4
healthy children, all with no known autoimmune or genetic conditions.
Forty-one patients with JIA (14 male, 27 female), all fulfilling the Inter-
national League of Associations for Rheumatology classification criteria
(15), were included in this study. Four patients gave only PBMC samples and
seven provided both PBMC and SF mononuclear cell (SFMC) samples.
Seven patients contributed more than one SF sample. See Supplemental
Table I for detailed patient characteristics.
For disease severity analysis, 45 SF samples were analyzed, of which 18
were from patients with the persistent oligoarticular subtype, 16 with ex-
tended oligoarticular JIA, and 11 with polyarticular JIA. For clinical se-
verity analysis, the patient’s diagnosis at the time of sampling was
identified (including seven patients with serial samples); the polyarticular
and extended oligoarticular patient samples were combined as a group
because all had more than five joints involved, that is, polyarticular course
of disease (more severe, n = 27, 70.4% female), and they were compared
with the patient samples identifying with the mild remitting persistent
oligoarticular JIA subtype (n = 18, 61.1% female).
SFMCs and PBMCs were prepared by density gradient centrifugation
using LymphoPrep (Axis-Shield) with SF samples undergoing pretreatment
with hyaluronidase (10 U/ml; Sigma-Aldrich) (6).
Flow cytometry and cell sorting
Flow cytometry was performed with the following directly conjugated
Abs: CD3 (clone UCHT1) V450/V500 (both BD Biosciences); CD3-PC7
(Beckman Coulter); CD4-FITC (RPA-T4) (eBioscience); CD4 (clone
OKT4)-BV711 (BioLegend); CD4 (clone SFCI12T4D11)-PC7 (Beckman
Coulter); CD4 (clone S3.5)-QDOT605 (Life Technologies); CD25 (clone
M-A251)-PE/allophycocyanin (BD Biosciences); BV421 (BioLegend);
CD127 (clone eBioRDR5)-FITC/eFluor 450 (eBioscience); FOXP3 (clone
236A/E7)-allophycocyanin/eFluor 450 (eBioscience); CTLA-4 (clone
14D3)–PE (eBioscience); Ki67 (clone 20Raj1)-eFluor 450 (eBioscience);
programmed cell death-1 (PD-1; clone EH12.2H7)–BV605 (BioLegend);
p-STAT5 (clone 47/Stat5[pY694])-PE (BD Biosciences); LAP (clone
FNLAP)–PE-Cy7 (eBioscience); IL-2 (clone MQ1-17H12)-PE (eBio-
science); IL-17A (clone BL168)-BV605 (BioLegend); ubiquitin-specific
peptidase 7 (USP7; polyclonal) unconjugated (Bethyl Laboratories) or
goat anti-rabbit Alexa Fluor 488 for USP7 detection using standard tech-
niques (see Ref. 16). CTLA-4 staining was performed intracelluarly using
the eBioscience FOXP3 staining buffers. Cytokine staining was performed
after 2 h of stimulation with 50 ng/ml PMA and 500 ng/ml ionomycin in
the presence of 5 mg/ml brefeldin A (all Sigma-Aldrich) before fixation
and staining for IL-17A and IL-2 using eBioscience FOXP3 staining
buffers. Cell sorting was performed on a FACSAria machine after pre-
enrichment of CD4+ T cells by immunomagnetic negative selection
(StemCell Technologies).
For sorting of cells based on FOXP3 staining, after CD4+ T cell en-
richment, cells were stained with Live/Dead fixable blue dead cell stain
followed by labeling at 4˚C with CD4, CD127, and CD25 Abs. Cells were
then fixed for 30 min using 1 ml FOXP3 Fix/Perm reagent (eBioscience)
before washing and labeling with allophycocyanin-conjugated anti-FOXP3
(clone 236A/E7) for 45 min. Single “live” CD127lo cells were selected for
sorting Treg populations according to CD25 and FOXP3 expression status:
P1, CD25loFOXP3hi; P2, CD25hiFOXP3hi; P3, CD25hiFOXP3lo. Tcons
were sorted as CD127hiCD25loFOXP3lo.
Multispectral imaging flow cytometry
Cells were stained using standard protocols as previously described (see
Ref. 16). Multispectral imaging flow cytometry was performed on an
Amnis ImageStreamX Mark II instrument. Cells were gated on aspect ratio
to include only single cells, and the gradient root-mean-square feature was
based on DAPI staining to include focused cells. A CD3+CD4+ gate was
then constructed and 1 3 104 images were acquired.
Detection of phosphorylated STAT5 by flow cytometry
Cryopreserved SFMCs were thawed, washed, and resuspended in plain
RPMI 1640 at a density of 5 3 106/ml in FACS tubes (BD Biosciences).
Cells were incubated for 15 min at 37˚C before stimulation with 100 U/ml
recombinant human IL-2 (Roche) for 15 min. Stimulation was stopped by
the addition of paraformaldehyde to a final concentration of 1.5% and
a further incubation at 37˚C for 15 min. Cells were pelleted, permeablized
in 90% ice-cold methanol for 15 min on ice, followed by two washes with
PBS and one wash with PBS/2.5% FBS. Cells were then stained for 40 min
at 4˚C with Abs to CD3, CD4, CD25, FOXP3, and p-STAT5.
DNA extraction
For isolation of DNA from live, unfixed cells, a Qiagen DNeasy blood and
tissue kit was used. For isolation of DNA from fixed and permeablized cells,
a published protocol was used with minor modifications (17). Sorted cells
were incubated with 300 ml lysis buffer (10 mM Tris-HCl, 100 mM NaCl,
50 mM EDTA, 0.5% SDS, 0.1 mg/ml proteinase K [Roche], and 20 mg/ml
RNase A [Qiagen], pH 8.0) for 24 h at 60˚C on a thermo-shaker. The lysis
solution was mixed vigorously with one volume of phenol/chloroform/
isoamyl alcohol (25:24:1; Sigma-Aldrich) and the phases were separated
by centrifugation at 13,000 rpm for 5 min at room temperature. The aqueous
phase was removed and mixed with one volume of chloroform/isoamyl al-
cohol (24:1), phases were separated by centrifugation at 13,000 rpm for 5 min
at room temperature, and the aqueous phase was removed and DNA pre-
cipitated by addition of ethanol to a final concentration of 75%. Tubes were
incubated at 220˚C for at least 4 h, before DNA was pelleted and washed
twice with 70% ethanol. DNA pellets were air-dried before dissolving in TE
buffer (Sigma-Aldrich), pH 8.0, for at least 24 h at room temperature.
Bisulfite treatment and methylation analysis
Male patients (patients 5, 9, 24, and 28) were chosen for TSDR analysis, and
patients 24 and 28 were chosen for promoter analysis. DNA was bisulfite
treated using the EpiTect bisulfite kit (Qiagen). A 336-bp segment containing
the TSDR of FOXP3 was amplified (FOXP3 TSDR, forward, 59-TGT TTG
GGG GTA GAG GAT TT-39, reverse, 59-TAT CAC CCC ACC TAA ACC
AA-39) (11) or the FOXP3 promoter (FOXP3 promoter, forward, 59-TGG
TGA AGT GGA TTG ATA GAA AAG G-39, reverse, 59-TAT AAA AAC
CCC TCC CCA CC-39) (10) by platinum high-fidelity Taq (Invitrogen),
followed by cloning of PCR products (TOPO TA kit). Clones were sequenced
using M13 primers, and sequences were aligned (reverse complementation
was accepted) to an imputed TSDR/promoter sequence using Geneious Pro
5.6.6 software (Biomatters). The retention of a C nucleotide at the CpG
position identified methylated CpG sites; the presence of a T nucleotide
identified unmethylated CpGs. The percentage of clones displaying methyl-
ated CpG for each site, as well as total average, was then determined. For
TSDR analysis, a mean of 21–24 clones per subset per patient was performed.
In vitro Treg suppression assays
To assess proliferation of Tcons, Tcons (CD4+CD127hiCD25lo) were la-
beled in 1 mM CFSE solution as previously described (see Ref. 18). La-
beled Tcons were cultured at a constant number of 5 3 104/well either
alone (1:0) or at a 1:2, 1:4, and, where cell numbers permitted, 1:8 ratio
with either P2-enriched Tregs or P3-enriched Tregs on V-bottom 96-well
plates (Costar) precoated with 1 mg/ml anti-CD3 (clone UCHT1, R&D
Systems) and 5 mg/ml anti-CD28 (clone CD28.2, BD Biosciences) Abs in
culture medium (RPMI 1640 supplemented with 10% FBS and 100 U/ml
penicillin/streptomycin) at 37˚C and 5% CO2 for 4–5 d. Final cell con-
centration was maintained at 1 3 106/ml. A cytokine multiplex assay was
performed as previously described (19).
In vitro culture of Tcons and TSDR methylation assessment of
Tcons
Cells (CD4+CD127hiCD25lo) were isolated from healthy control PBMCs and
cultured on anti-CD3 (1 mg/ml)– and anti-CD28 (5 mg/ml)–coated 96-well V-
bottom plates at a density of 5 3 105 T cells/ml in the presence of 100 U/ml
recombinant human IL-2. On day 7, cells were harvested, stained for CD4,
CD25, and FOXP3, plus Live/Dead fixable blue dead cell stain, and CD25hi
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FOXP3hi and CD25hiFOXP3lo CD4+ T cells were sorted on a FACSAria cell
sorter. From the sorted populations, DNAwas extracted, bisulfite treated, and
the TSDR was amplified, cloned, and sequenced as described above.
RNA extraction and RT-PCR analysis
RNA was extracted from sorted cells according to the manufacturer’s in-
structions (TRIzol, Invitrogen) and converted to cDNA as described (see Ref.
18). Primer sequences were: FOXP3 mRNA, forward, 59-ACC TGG AAG
AAC GCC ATC-39, reverse, 59-TGT TCG TCC ATC CTC CTT TC-39;
USP7 (20), forward, 59-GCA AGT GCAGATAGT CGC AGAGGACC-39,
reverse, 59-CCA TGG TCT GAG AGA GGC TCT GAA C-39. Gene ex-
pression is displayed relative to GAPDH (Qiagen) using the 22DCt method.
SF Treg culture with IL-2 or proteasome inhibitor MG132
P2 and P3 Tregs were enriched as described above and cultured on 96-well V-
bottom plates for 24 h in the presence of medium alone, 2 U/ml recombinant
human IL-2, DMSO, or 5 mMproteasome inhibitor MG132 (Sigma-Aldrich).
Statistical analysis
Statistical analysis was performed on Prism 5 for Macintosh software
(GraphPad Software). For clarity, statistical tests and error bar descriptions
are included in the figure legends. A p value,0.05 was deemed statistically
significant.
Results
Dissociation of CD25 from FOXP3 expression on CD4+ T cells
Analysis of SF and peripheral blood CD4+ T cells from JIA patients
demonstrated that the CD25hi and FOXP3hi (Fig. 1A) populations
are contained within the CD127lo population. Gating on the CD4+
CD127lo population (Fig. 1B), we observed a marked dissociation of
FOXP3 from CD25 in SFMC samples (Fig. 1B) but not in autologous
PBMCs. Further analysis of a representative SFMC sample by mul-
tispectral imaging flow cytometry validated the flow cytometry data,
where the presence of four distinct populations based on the imaging
of CD25 and FOXP3 staining are clearly identifiable (Fig. 1C).
The epigenetic footprint of FOXP3+ Tregs is not limited to the
CD25hiFOXP3hi T cell compartment
Because T cell activation can elicit FOXP3 expression in Tcons (9),
we wanted to determine the frequency of bona fide FOXP3+ Tregs
at the inflamed site. Although there is no single, exclusive Treg
marker, the methylation status of the TSDR is a widely used test
for distinguishing between activated T cells and bona fide Tregs.
SFMCs were stained for the surface markers CD4, CD25, and
CD127 and then fixed, permeablized, and stained for FOXP3 be-
fore sorting into four subsets (Fig. 2A), hereafter referred to as fol-
lows: P1, CD127loCD25loFOXP3hi; P2, CD127loCD25hiFOXP3hi;
P3, CD127loCD25hiFOXP3lo; and a control population, Tcon,
CD127hiCD25loFOXP3lo, as represented in Fig. 1C. Purities of a
representative sort (Fig. 2A) and the summary of FOXP3 and CD25
expression are shown (Fig. 2B, Supplemental Fig. 1A).
DNA was extracted from sorted populations before bisulfite
treatment for methylation analysis. Complete methylation was seen
in the Tcon population (median, 95.45%). However, interestingly,
extensive demethylation was not restricted to the P2 population
(Fig. 2C, 2D): the P2 population displayed complete demethylation
(median, 3.57%) whereas the P1 population (median, 12.80%) and
P3 CD4+ T cells (median, 21.3%) also showed extensive deme-
thylation despite the latter two populations returning a small num-
ber of clones containing methylated sequences (Supplemental Fig.
1B), indicating that a proportion of these cells may be contami-
nating activated Tcons. Similar findings regarding ex-FOXP3
T cells have recently been observed in mice (21); however, to our
knowledge, this is the first demonstration in humans of a T cell
population displaying a decoupling of TSDR demethylation from
stable FOXP3 protein expression.
We also investigated the differentially methylated region at the
FOXP3 promoter (10) and similar to P2 Tregs, both P1 and P3
Tregs displayed demethylation at this region (Supplemental Fig.
1C). Interestingly, Tcons also displayed considerable demethyla-
tion at several CpG positions, but, as reported by Janson et al.
(10), the 277 position was discriminatory with 50% methylation
in Tcons compared with ,10% in P1–P3 Tregs.
Using an in vitro culture system, we confirmed that activation of
Tcons does not promote significant demethylation in T cells re-
gardless of FOXP3 expression levels. In vitro–generated CD25hi
FOXP3lo and CD25hiFOXP3hi cells both showed high levels of
methylation (Supplemental Fig. 2).
P3 T cells display phenotypic characteristics of an activated Treg
We further examined the phenotype of the three putative Treg
populations by assessing intracellular CTLA-4 expression (Fig. 3A).
P2 and P3 Tregs exhibited significantly higher levels of total
FIGURE 1. Dissociation of CD25 and FOXP3 expression at the inflamed site. Flow cytometry data, gated on CD3+CD4+ T cells, of paired SFMC and
PBMC samples from a JIA patient displaying (A) CD25 versus CD127 expression (left) and FOXP3 versus CD127 expression (right). Because FOXP3hi
and CD25hi cells are almost uniformly CD127lo, a CD4+CD127lo gate (B, left) was set to analyze the relationship between FOXP3 and CD25 expression (B,
right). (C) Multispectral imaging flow cytometry was performed on CD4+ T cells from SFMCs of a JIA patient. Four representative image panels are
displayed illustrating the four populations identifiable by the imaging of CD25 and FOXP3 staining. Brightfield (BF), CD25, and FOXP3 images were
merged, with BF intensity set to 40% and CD25 and FOXP3 at 100%.
The Journal of Immunology 2701
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CTLA-4 compared with CD127hi T cells at the inflamed site
whereas, interestingly, P1 Tregs exhibited an intermediate level
of CTLA-4, which was significantly lower than that of P2 Tregs.
Based on high CD25 and CTLA-4 expression, as well as a
demethylated TSDR but low FOXP3 expression, we hypothesized
that P3 Tregs may represent a chronically activated FOXP3lo Treg
phenotype. The marker PD-1 can be expressed on chronically
stimulated CD8 T cells and is associated with T cell exhaustion
in HIV-infected individuals (22). We therefore determined the
expression levels of PD-1. Whereas PD-1 expression on all SF
CD127loCD25hi cells was significantly higher than on controls
(Fig. 3B), we observed significantly higher levels of PD-1 on the
P3 Tregs compared with P1, P2, or CD127hi T cells (Fig. 3C).
P3 Tregs display a modest functional inferiority compared with
P2 Tregs
To examine the regulatory potential of the FOXP3lo cells observed
at the site of inflammation, we required a way to separate viable
cells. We hypothesized that higher levels of PD-1 could facilitate
the separation of the CD25hi population into FOXP3hi and FOXP3lo
populations in the patient samples displaying the biggest differ-
ences in PD-1 median fluorescence intensity (MFI) between the
two Treg populations. Additionally, during postsort purity analy-
ses we noted that P3 Tregs had higher forward light scatter (FSC)
characteristics than did P2 Tregs. We therefore developed a sort
strategy to separate the CD25hi population into FOXP3hi and
FOXP3lo populations (Figs. 4, 5A, Supplemental Fig. 3A), en-
abling an estimation of their functional capacities. To validate that
this sort strategy did enrich for TSDR demethylated T cells, TSDR
analysis was performed on cells from patient 21 (Fig. 5B). Post-
sort expression of CD25, FOXP3, and PD-1 were also analyzed.
Significant differences were found in PD-1 MFI (.8-fold, as
expected) and FOXP3 MFI (.4-fold, as predicted), but not in
CD25 expression (Fig. 5C, 5D).
P2- and P3-enriched Tregs were tested for their ability to inhibit
Tcon proliferation (Fig. 5E–G) and cytokine secretion (Fig. 5H) at
a range of Treg/Tcon ratios. Both subsets significantly suppressed
Tcon proliferation at a 1:2 ratio of Tregs to Tcons (Fig. 5E, 5F).
Titration of Tregs suggested that the suppressive capacity of P3-
enriched Tregs was lower than that of P2 at the lower Treg/Tcon
ratio of 1:8; however, the differences between P2 and P3 did not
reach statistical significance (p = 0.0787 [paired t test] at a 1:8
ratio, Fig. 5G).
Supernatants from these cultures were analyzed for levels of
IFN-g, IL-17A, and TNF-a by cytokine multiplex assay. Both P2-
and P3-enriched Tregs suppressed IFN-g and TNF-a production
to a similar degree; however, there was a significant difference in
the suppression of IL-17A at the 1:8 Treg/Tcon ratio (p = 0.0215)
between P2 and P3 Tregs (Fig. 5H). Given the recent reports that
FOXP3 protein downregulation can lead to a de-repression of
cytokine genes, such as IL-2 (20), we investigated cytokine pro-
duction by P1–P3 Tregs (Supplemental Fig. 3B, 3C). We found no
difference in latency-associated peptide expression, but IL-2– and
IL-17A–producing cells were slightly increased in frequency in P3
Tregs when compared with P2, which in part could have con-
tributed to the differences in the suppression of IL-17A secretion.
Of note, P2-enriched Tregs maintained their FOXP3hi phenotype
during the in vitro culture, and interestingly P3-enriched Treg
FOXP3 protein levels remained significantly lower (FOXP3 MFI at
1:2 ratio of 2433.5 versus 799.8 for P2 versus P3 Tregs, p , 0.01).
Defective IL-2 signaling in P3 Tregs
Our results suggested that high FOXP3 expression is not essential
for the capacity of T cells to act as regulators, but that it may be
FIGURE 2. The epigenetic footprint of Tregs is not limited to the CD25hiFOXP3hi CD4+ T cell compartment. CD4+ T cells were isolated from a JIA
SFMC sample, stained for CD4, CD25, and CD127, before fixation and staining for FOXP3. Cells were then sorted into four populations based on CD25
and FOXP3 expression. (A) Representative sort displaying the presort staining (far left, gated on CD4+CD127lo T cells) and postsort purities (right four
plots). The cellular phenotypes were further analyzed for FOXP3 and CD25 protein expression levels. (B) Summary plots of MFI data (n = 3–4):O, P1
Treg; d, P2 Treg; N, P3 Treg; 3, Tcon. (C) TSDR methylation rates were determined in the sorted populations from one patient (patient 24) and are
presented as heat maps plus region average. (D) Summary of the mean TSDR methylation rates in P1–P3 Tregs and Tcons in the four patients studied
(patients 5, 9, 24, and 28). P1 Tregs, n = 3 (amplification of the TSDR from P1 Tregs in patient 9 was unsuccessful); P2 Tregs, n = 4; P3 Tregs, n = 3 (patient
5 was excluded from analysis based on a purity of ,50%); and Tcons, n = 4. Bars represent the median values.
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important for optimal suppression. We next explored possible
mechanisms to explain the loss of FOXP3 expression in P3 Tregs.
Two recent studies have highlighted a previously unappreciated
role for the ubiquitin pathway in regulating FOXP3 expression (20,
23). We hypothesized that if posttranslational mechanisms were
dominant in regulating FOXP3 protein levels, then mRNA levels
for FOXP3 should be comparable between P2 and P3 Tregs; al-
ternatively, if transcriptional regulation were the primary mecha-
nism, then FOXP3 transcript levels should be significantly lower
in P3 versus P2 Tregs. Analysis of expression levels of FOXP3
in P2- and P3-enriched Treg populations showed that FOXP3 pro-
tein levels and relative FOXP3 mRNA expression were both sig-
nificantly lower in P3-enriched Tregs (Fig. 6A). This finding,
however, did not exclude the possibility that posttransla-
tional mechanisms may also play a role in regulating FOXP3. The
deubiquitinase USP7 is upregulated in Tregs and prolongs the
half-life of FOXP3 protein by reducing its ubiquitin-mediated
degradation rate (20). We measured the levels of USP7 mRNA
by RT-PCR (Fig. 6B) and flow cytometry (Fig. 6C) and found that
P3 Tregs exhibited a significantly lower level of USP7 compared
with healthy control or P2 Tregs. To assess whether protein deg-
radation was an important factor in generating the P3 phenotype,
we cultured P3-enriched Tregs with the proteasome inhibitor
MG132: however, we observed no increase in FOXP3 staining
after culture in MG132, which may be in part due to the toxicity of
MG132 to SF Tregs (Fig. 6D). These findings collectively suggest
that maintenance of USP7 expression may be important for opti-
mal FOXP3 expression at the inflamed site, but that proteasomal
degradation alone may not explain the FOXP3lo phenotype.
We next considered the transcriptional regulation of FOXP3
expression. The importance of IL-2 in maintaining FOXP3 ex-
pression is well established (24). Because both P2 and P3 Tregs
expressed high levels of CD25, we hypothesized that both should
be able to respond to IL-2. We determined whether IL-2 exposure
would be sufficient to recover FOXP3 expression in P3 Tregs.
Both P2- and P3-enriched Tregs were sorted from SF and cultured
for 24 h with or without IL-2, and expression of CD25 and FOXP3
was analyzed (Fig. 7A, 7B). P2-enriched Tregs displayed a modest
increase in FOXP3 expression and a positive shift in CD25 ex-
pression in response to IL-2; however, P3-enriched Tregs showed
no increase in FOXP3 levels and a nonuniform increase in CD25
expression. The observation of this bimodal response to IL-2, as
well as a previous report that Tregs in patients with autoimmunity
can display defective IL-2 signaling (25), led us to hypothesize
that a proportion of P3 Tregs may have a defect in signaling in
response to IL-2. We therefore examined IL-2–induced STAT5
phosphorylation in SF T cells (Fig. 7C, 7D).
SFMCs from JIA patients were cultured with IL-2 before
analysis (Fig. 7C, 7D). P2 and P1 cells exhibited robust responses
to IL-2 with .90% of cells responding, as indicated by phos-
phorylation of STAT5 (Fig. 7C). In contrast, P3 cells exhibited
a median 65.8% response, which was significantly lower than the
P1 or P2 Tregs, and even had a trend to lower STAT5 phosphor-
ylation levels than did Tcons (median, 79.15%; Fig. 7D, left).
Levels of p-STAT5 protein quantified by MFI followed the same
significant patterns (Fig. 7D, right).
Given the critical role for IL-2 in promoting Treg homeostasis, we
hypothesized that P3 Tregs would display diminished turnover
in vivo. Both P1 and P2 Treg populations had a significantly higher
rate of turnover compared with CD127hi T cells (median frequen-
cies: P1, 21.00%; P2, 23.60%; CD127hi, 3.65%) whereas P3 ex-
hibited intermediate turnover (median frequency, 9.28%), which
was not significantly different from Tcons (Fig. 7E), suggesting that
defects in IL-2 sensitivity may result in a failure to maintain FOXP3
expression and reduced proliferative potential for P3 Tregs.
Increased proportions of P3 Tregs in the more severe forms of
childhood arthritis
To understand the clinical significance of P3 Tregs, we next an-
alyzed the frequency of the Treg populations in control subjects as
well as peripheral blood and SF of patients with JIA. All three
populations were significantly increased in frequency in the in-
flammatory compartment compared with controls or JIA PBMCa,
although P1 and P3 SF Treg frequencies displayed non-Gaussian
distributions (Fig. 8A).
We next investigated whether the proportions of FOXP3lo Tregs
within the CD25hi T cell compartment had any relationship to
disease severity in JIA. It has been previously demonstrated that
the milder form of oligoarticular JIA (O-JIA), called persistent
O-JIA, is associated with an increased frequency and number of
Tregs in the inflamed compartment (5, 6) compared with the more
severe forms of disease; however, these studies did not stratify
according to FOXP3 high or low expression. We observed a sig-
nificantly increased proportion of FOXP3lo T cells within the
CD127loCD25hi T cell compartment in patients with more severe
disease (median, 31.97 versus 22.92%, p = 0.0239) when the
samples were split according to the disease severity at the time
of sampling (severe, polyarticular disease course; mild, persistent
FIGURE 3. P3 T cells display phenotypic characteristics of an activated
FOXP3lo Treg. (A) Histogram displaying CTLA-4 levels in the three pop-
ulations (P1, gray dashed line; P2, black line; P3, gray line) compared with
CD127hi T cells (black dashed line) in one representative patient. Summary
graph (right) displays the MFI of CTLA-4 in the four populations described
(n = 9). (B) Representative histogram overlays (left) displaying PD-1 ex-
pression levels within the CD4+CD127loCD25hi subset in healthy control
PBMC (black dashed line), JIA PBMC (gray line), and JIA SFMC (black
line) samples; right, summary graph of PD-1 MFI levels (adult controls, n = 6;
JIA PBMCs, n = 5; JIA SFMCs, n = 20). (C) Representative histogram
overlays (left) showing PD-1 expression (numbers display the MFI) within the
four subsets (P1, gray dashed line; P2, black line; P3, gray line; CD127hi
T cells, black dashed line); right, summary graphs of (n = 24) PD-1 protein
expression level (MFI). Bars represent median values. Statistical analysis by
Friedman test with Dunn’s multiple comparisons (A and C) or Kruskal–Wallis
test with Dunn’s multiple comparisons (B). **p , 0.01, ***p , 0.001.
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O-JIA; Fig. 8B). Although the frequency of patients on methotrexate
at the time of sampling was increased in the polyarticular course
group compared with the persistent JIA group, this did not reach
statistical significance (55.6 versus 27.8%, p = 0.077, Fischer exact
test). This result suggests that the presence of FOXP3lo Tregs within
the CD25hi Treg compartment may have consequences for disease
pathogenesis.
Discussion
The stability of the FOXP3+ Treg lineage has been a controversial
issue for some time. We have demonstrated that high levels of
CD25 and FOXP3 coexpression successfully identify committed
and functional Tregs, even at the site of inflammation; however,
within the CD25hi population there is a notable decoupling of
TSDR demethylation from FOXP3 expression in a subset of cells.
FIGURE 4. PD-1 expression and FSC characteristics partition the CD25hiCD4+ SF T cell compartment into P2 and P3 Treg subsets. Displayed is an SFMC sample
stained for CD4, CD127, CD25, FOXP3, and PD-1 and analyzed by flow cytometry. (A) Boolean gating strategy used to obtain the CD127loCD25hiCD4+ T cell
population. (B) Flow cytometry plots gated on CD4+CD127loCD25hi SF T cells displaying FOXP3 versus FSC (left) and FOXP3 versus PD-1 expression (right).
Intrasample correlations were analyzed by the Spearman rank correlation analysis; n = 1856 data pairs. ****p , 0.0001. (C) Flow cytometry data gated on
CD4+CD127loCD25hi SF T cells (left) displaying PD-1 versus FSC expression. Flow cytometry plots (right) display CD25 versus FOXP3 expression on the
cells in the gates P2 and P3.
FIGURE 5. P3 Tregs display a modest functional deficit. (A) Flow cytometry plots displaying CD25 versus FOXP3 expression in unsorted sample from
patient 21 (left), P2-enriched Tregs, CD127loCD25hiFSCloPD-1int (middle), and P3-enriched Tregs, CD127loCD25hiFSChiPD-1hi (right). (B) TSDR
methylation rates in sorted Treg populations from patient 21. (C) Representative histogram overlays (top) displaying expression levels of PD-1, FOXP3, and
CD25 in the sorted Treg populations compared with autologous SF Tcons (P2, black line; P3, gray line; CD127hi T cells, black dashed line). (D) Summary
graphs show MFI data for PD-1, FOXP3, and CD25 in the sorted samples (n = 6). CFSE-labeled SF Tcons were cultured alone (0:1) or at a 1:2, 1:4, or 1:8
ratio with either P2 Tregs or P3 Tregs on anti–CD3/CD28-coated plates for 4–5 d. (E) Histogram overlay displaying Tcon CFSE dilution in the presence of
P2 Tregs (black line) and P3 Tregs (gray line) at a 1:2 ratio. Tcon alone division is displayed in black dashed line. (F) Summary data demonstrating
percentage of divided Tcons in the presence of P2 (filled bar) or P3 (open bar) Tregs (n = 6) or no Tregs (hatched bar). (G) Percentage suppression of SF
Tcons at 1:2 (n = 6), 1:4 (n = 6), and 1:8 (n = 5) Treg/Tcon ratios. (H) Levels of IFN-g, IL-17A, and TNF-a in coculture supernatants. Tcons plus P2 Tregs
(d) and Tcons plus P3 Tregs (N) are shown. Bars represent the median value in (D) and means 6 SEM in (F)–(H). Statistical analysis was performed by
a Mann–Whitney U test (D), repeated measures ANOVA with a Bonferroni multiple comparisons test (F), or a paired t test (H). *p , 0.05, **p , 0.01.
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Our data strongly support the case that this CD25hiFOXP3lo TSDR
demethylated population is a FOXP3lo Treg population that we
speculate may have downregulated FOXP3 in the inflammatory
environment.
Another striking feature of this study is the considerable het-
erogeneity in Treg subsets that is present at the inflamed site in
humans. Whereas PBMCs show more discrete clusters, it is clear
that the proportions of P1–P3 Tregs vary considerably between
FIGURE 6. Decreased FOXP3 mRNA and expression of USP7 in P3 Tregs. RNA was extracted from P2- and P3-enriched Treg populations and
converted to cDNA. (A) FOXP3 protein MFIs (d) and mRNA levels of FOXP3 (relative to GAPDH) (N) in P2- and P3-sorted subsets (n = 4). (B) Relative
levels of USP7 mRNAwere analyzed by RT-PCR in P2-enriched Tregs (n = 6), P3-enriched Tregs (n = 4), or healthy control Tregs (n = 3). (C) Left, Flow
cytometry plot showing CD25 versus FOXP3 staining gated on CD4+ T cells in a SF sample, with gates for P1, P2, and P3 Tregs. Center, Histogram overlay
showing USP7 staining in P1 (gray dashed line), P2 (black line), or P3 Tregs (gray line). Numbers represent MFIs (n = 3). Right, Summary data showing
MFI. (D) To examine FOXP3 degradation, P3-enriched SF Tregs were cultured for 24 h in the presence/absence of 5mM proteasome inhibitor MG132.
Expression of FOXP3 versus Live/Dead dye was analyzed by flow cytometry. Statistical analysis performed by a Mann–Whitney U Test (A) or a one-way
ANOVA with a Bonferroni multiple comparisons test (B and C). *p , 0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001.
FIGURE 7. Decreased IL-2 responsiveness in P3 Tregs. (A) P2- and P3-enriched SF Tregs were isolated as previously described and cultured for 24 h
with or without 2 U/ml IL-2. Histograms of Tregs 24 h after culture displaying FOXP3 (A) or CD25 (B) expression are shown. To assess IL-2 sensitivity,
total SFMCs from JIA patients were stimulated with 100 U/ml recombinant human IL-2 for 15 min. (C) Flow cytometry plot (left) gated on CD3+CD4+
T cells, showing CD25 versus FOXP3 expression. Histogram (right) displaying p-STAT5 levels in stimulated P1 (gray dashed line), P2 (black line), and P3
(gray line), or CD25loFOXP3lo T cells (black dashed line); unstimulated T cell p-STAT5 levels are represented by the filled histogram. (D) Summary graphs
of percentage p-STAT5+ (left) or MFI of p-STAT5 protein (right) in the four different T cell populations (n = 10; data are from five independent
experiments). (E) Graph of percentage Ki67+ cells in the three Treg subsets compared with CD127hi T cells (n = 19). Bars display median values. Statistical
analysis was performed by Friedman test with Dunn’s multiple comparisons test (D and E). *p , 0.05, **p , 0.01, ***p , 0.001.
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individuals, as well as each subset displaying its own heteroge-
neity within (notably P3 Tregs). A possible explanation for this is
that the cells may arise from differing local environments within
the joint or may be in differing stages of activation.
One unifying feature, however, of P1–P3 Tregs is that they are
predominantly CD127lo, which is interesting given the observations
that some Tregs can upregulate CD127 upon activation in mice
(26). In our hands, a common theme is that the joint environment
promotes a downregulation of CD127 and a concomitant upregu-
lation of CD25. Indeed, factors that govern the expression at the
inflamed site of these receptors warrants further investigation, given
the importance of common g-chain cytokines to T cell survival.
Our data demonstrate that the P1 and P3 phenotypes are largely
confined to the inflamed envrionment. One limitation when working
with human SF is the absence of an appropriate biological control.
The joints of healthy individuals are largely acellular, and ethical
implications preclude the removal of SF from healthy controls. It will
be interesting to compare across other diseases, including both
autoimmune and nonautoimmune inflammatory disorders, as to
whether the P3 Treg is a consequence of chronic inflammation, or is
particular to autoimmunity. Furthermore, although this study has
focused on P3 Tregs, it is clear that CD25lo Tregs (P1) are also of
interest and worth investigating. Such cells have been reported in
the blood of lupus patients (27, 28), and therefore further work is
required to understand the co-regulation of CD25 and FOXP3 ex-
pression on Tregs, and how this may become dysregulated. We
would hypothesize from our data that P1 Tregs represent a P2 Treg
population that has downregulated CD25 expression.
It is increasingly clear that the maintenance of high FOXP3
expression in Tregs is complex and dependent on multiple factors.
Undoubtedly epigenetic modifications are important players in
determining the stable commitment of Tregs; in this case, the
TSDR status (11, 12, 29) has been widely used to define stable
FOXP3+ Tregs. Although it is known that epigenetic programming
of Tregs is essential for their development (29), our data show that
TSDR demethylation alone is not sufficient in itself to maintain
high FOXP3 protein expression, and other factors affecting both
transcription and protein stability are defective in a subpopulation
of CD25hi Tregs.
The observed loss of FOXP3 protein expression in Tregs does not
necessarily support the conclusion that the entire Treg program is
intrinsically “unstable” at the inflamed site, but reflects the com-
plexity of the regulation of FOXP3 expression, and also that
a Treg is more than just a FOXP3-expressing cell (29). P3 Tregs
display many characteristics of Tregs, and as such we do not think
that they represent an ex-Treg population, but speculate that they
may represent a FOXP3+ Treg that has downregulated FOXP3 but
retains many features of Tregs, including the ability to suppress
immune responses. Although in this study we cannot prove that P3
Tregs have previously expressed FOXP3, the concept of an ex-
FOXP3 T cell has been reported in mice (30), and such cells can
re-express FOXP3 following culture in vitro (21). The authors
suggested that epigenetic modifications to the FOXP3 locus might
serve to maintain Treg lineage commitment by imprinting mem-
ory for FOXP3 (and thus Treg commitment) regardless of ongo-
ing FOXP3 expression. Our findings are consistent with these
observations, because TSDR and promoter demethylated human
FOXP3lo Tregs still displayed suppression in vitro. Furthermore,
fate mapping in mice has shown that, at the very least, a clear
subset of the Treg lineage maintains stable FOXP3 transcription,
even under inflammatory conditions (31). Most fate-mapping
studies, however, have deployed genetic constructs that use tran-
scriptional readout for FOXP3 expression, and they cannot be
solely relied upon to predict FOXP3 protein stability. Recent in-
sight into the posttranslational control of FOXP3 protein may
explain reported differences in studies investigating Treg FOXP3
expression stability, as several groups have documented that in-
flammatory insults, such as LPS challenge, IL-6, or CCL3, can
trigger the ubiquitination and degradation of FOXP3 protein,
which can downmodulate Treg function without affecting FOXP3
gene expression (20, 23, 32). Analysis of these Treg populations
by transcriptional methods alone would have failed to identify this
downregulation of FOXP3 protein.
The in vivo consequences of human Treg FOXP3 downregu-
lation are difficult to gauge since the studies of human Treg
suppression are largely limited to the in vitro setting. Our data
suggest that although P3 Tregs are suppressive in an ex vivo culture
system, their performance in vivo may be compromised, as in-
creased proportions of FOXP3lo Tregs are found in patients with
more severe disease course of JIA. It is clear from the literature
that many immune cell populations displaying robust in vitro
suppressive capacity are unable to regulate in vivo, where fac-
tors in addition to FOXP3 stability, such as cellular migration,
turnover, Ag specificity, and survival, are likely to be important.
To this end, there is a great need to develop more sophisticated
assays to investigate human Treg function.
We observed that P3 Tregs displayed reduced sensitivity to IL-2
signals, and this in part may explain why IL-2 stimulation was
insufficient to recover FOXP3 protein levels in these cells despite
the well-known report that IL-2 is critical for maintaining Treg
FOXP3 expression (24). Defects in IL-2 signaling have been ob-
served in patients with autoimmunity and have been attributed to
FIGURE 8. Increased proportions of FOXP3lo Tregs in the more severe forms of childhood arthritis. (A) Using the gating strategy determined in Fig. 1,
the frequency of P1, P2, and P3 Tregs within the CD4+CD127lo T cell compartment was determined in adult control PBMCs (n = 9), child control PBMCs
(n = 4), JIA patient PBMCs (n = 11), and JIA patient SFMCs (n = 45). Bars represent median values. (B) The proportion of FOXP3lo cells within the CD4+
CD127loCD25hi T cell compartment was analyzed according to disease severity at the time of sample: persistent O-JIA, n = 18; polyarticular JIA course, n = 27.
Statistical analysis by Kruskal–Wallis test with a Dunn’s multiple comparisons test (A) or Mann–Whitney U test (B). *p , 0.05, **p , 0.01, ***p , 0.001.
2706 DECOUPLING OF TSDR AND FOXP3 EXPRESSION IN HUMAN Tregs
 at U
CL Library Services on N
ovem
ber 24, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
increased expression of the phosphatase PTPN2 (25). In our
hands, experiments involving the phosphatase inhibitor sodium
vanadate did not alter IL-2 signaling in P3 Tregs (D. Bending,
unpublished observation), and the mechanisms behind this disrup-
tion in STAT5 responsiveness is of interest given that IL-2 is im-
portant not only in supporting FOXP3 expression but also for Treg
proliferation and survival. Although P2 Treg turnover at the
inflamed site is significantly higher than that of Tcons, as previously
reported (33), it is tempting to speculate that defects in IL-2 sig-
naling may also render P3 Tregs hypoproliferative, and the inability
of FOXP3lo Tregs to proliferate and upregulate FOXP3 in vivo may
affect their capacity to adequately respond to and control autoim-
mune responses. This has important ramifications for strategies
deploying adoptive Treg therapies to treat inflammatory disorders,
because transferred TSDR-demethylated Tregs may lose FOXP3
under conditions of stress or inflammation. It will be essential to
further clarify the precise mechanisms by which Tregs can lose
FOXP3 expression to optimize therapeutic strategies.
Past evidence in JIA suggests that the more severe form of
oligoarthritis (extended O-JIA) is associated with a reduced fre-
quency of Tregs compared with the milder form of disease (5, 6).
Clinical subtype analysis performed on all the SF samples in our
study revealed a significant correlation between the frequency of
FOXP3lo Tregs within the CD25hi T cell population and disease
course. We therefore hypothesize that the local environment may
play a critical role in regulating FOXP3 expression at inflamed
sites, and that some Tregs may downregulate FOXP3. We suggest
that the P3 Treg phenotype is analogous to a recently described
ex-FOXP3 Treg subset identified in experimental autoimmune
encephalomyelitis (30). It would be in keeping with murine
experiments that downregulation of FOXP3 in Tregs results in
reduced regulation and worsened disease, as evidenced experi-
mentally in models of type 1 diabetes, where Treg ablation leads
to almost immediate onset of disease (34). Gleaning a greater
knowledge regarding the nature of, and mechanisms involved in,
cells that lose FOXP3 in vivo will aid in our understanding of how
Tregs may fail to function adequately in disease settings.
We have described in the present study that stable FOXP3 ex-
pression is decoupled from TSDR demethylation in a population of
joint-infiltrating Tregs in human arthritis, and that the proportional
representation of such cells within the Treg subset correlates with
disease severity. Given the growing evidence that downregulation
or loss of FOXP3 in Treg populations is detrimental to the control
of chronic inflammation (20, 23, 34), future work should try to
clarify the mechanisms that occur in vivo to regulate CD25 and
FOXP3 expression. A detailed understanding of these processes
may yield new and unexpected therapeutic avenues to exploit for
the treatment of debilitating autoimmune diseases, such as JIA.
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Supplementary Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
ID SFMC PBMC Gender
Serial 
Samples JIA subtype Figures
1 No Yes M No Extended Oligo 3B, 8A
2 Yes No F No Polyarticular 3B, 3C, 7D, 7E, 8A, 8B
3 Yes Yes M Yes Extended Oligo
3B, 3C, 7A, 7B, 7D, 7E, 
8A, 8B, S3B
4 Yes No F No Extended Oligo 3A, 3B, 3C, 6B, 8A, 8B
5 Yes No M Yes Persistent Oligo 2B, 2D, 6C, 8A, 8B, S1A
6 Yes Yes F No Extended Oligo 3B, 3C, 7D, 7E, 8A, 8B
7 Yes No F No Extended Oligo 3A, 3B, 3C, 7D, 7F, 8A, 8B
8 Yes No F No Extended Oligo 3B, 3C, 8A, 8B
9 Yes No M No Extended Oligo 2B, 2D, 8A, 8B, S1A
10 Yes No F No Extended Oligo 3A, 3B, 3C, 7D, 7E, 8A, 8B
11 Yes No F No Persistent Oligo 3A, 3B, 3C, 7D, 7E, 8A, 8B
12 No Yes M No Persistent Oligo 8A 
13 No Yes M No Persistent Oligo 8A 
14 Yes Yes F No Persistent Oligo 3B, 3C, 8A, 8B
15 Yes Yes F yes Extended Oligo 3B, 3C, 7D, 7E, 8A, 8B
16 No Yes F No Persistent Oligo 3B, 3C, 8A
17 Yes Yes F Yes Extended Oligo
1A, 1B, 6C, 7C, 7D, 7E, 
8A, 8B
18 Yes Yes F Yes Extended Oligo 8A, 8B, S3B
19 Yes Yes F No Persistent Oligo 8A, 8B
20 Yes No F No Persistent Oligo 8A, 8B
21 Yes No M No Extended Oligo
3B, 3C, 4A-C, 5A-H, 7D, 
7E, 8A, 8B, S3A
22 Yes No M No Polyarticular
3A, 3C, 5D, 5F-H, 6A, 6B, 
8A, 8B, S3A
23 Yes No F No Persistent Oligo
3B, 3C, 5D, 5F-H, 6A, 6B, 
7D, 7E, 8A, 8B, S3A
24 Yes No M Yes Persistent Oligo
1C, 2A-D, 6C, 8A, 8B, S1A-
C
25 Yes No F No Persistent Oligo 3A-C, 7E, 8A, 8B
26 Yes No M No Persistent Oligo 8A, 8B
27 Yes No F No Persistent Oligo 3B, 3C, 7D, 7E, 8A, 8B
28 Yes No M No Persistent Oligo
2B, 2D, 7E, 8A, 8B, S1A, 
S1C
29 Yes No F No Persistent Oligo 8A, 8B
30 Yes No M No Extended Oligo 3B, 3C, 7D, 7E, 8A, 8B
31 Yes No F No Persistent Oligo
3A-C, 5D, 5F-H, 6A, 6B, 
8A, 8B, S3A
32 Yes No F No Persistent Oligo 8A, 8B, S3B
33 Yes No M No Persistent Oligo 3B, 3C, 7D, 7E, 8A, 8B
34 Yes No F No Persistent Oligo 3B, 3C, 7E, 8A, 8B
35 Yes No F Yes Polyarticular
3B, 3C, 5D, 5F-H, 6A, 6B, 
7A, 7B, 7E, 8A, 8B, S3A
36 Yes No F No Polyarticular 3B, 3C, 7E, 8A, 8B
37 Yes No F No Polyarticular 8A, 8B
38 Yes No F No Polyarticular 6A, 6B, 8A, 8B
39 Yes No F No Polyarticular 8A, 8B, S3B
40 Yes No M No Polyarticular
3B, 3C, 5D, 5F-H, 7E, 8A, 
8B, S3A
41 Yes No F No Polyarticular 3A, 3C, 8A, 8B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1: TSDR sequence traces reveal small presence of non-
Treg cells within P1 and P3 Treg populations, but complete demethylation at 
the FOXP3 promoter. 
(A) Purity of sorted T cell populations isolated from the synovial fluid of patients 5, 9, 
24 and 28 that were used for TSDR analysis in Fig. 2. (B) Displayed are 
representative TSDR sequences from 10 clones generated from the four T-cell 
populations in Fig. 2D from patient 24. Demethylated bases are shown in white, 
methylated CpGs are in grey tone. (C) FOXP3 promoter methylation status in the 
four T cell subsets from the synovial fluid of patients 24 and 28. 
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Supplementary Figure 2: In vitro-activated Tconv remain predominantly 
methylated at the TSDR irrespective of FOXP3 expression status.  
CD4+ T-cells were isolated from healthy donor PBMC and stained for CD4, CD25 
and CD127. Treg (CD25hiCD127lo) and Tconv (CD25loCD127hi) were sorted and a 
proportion of cells taken for TSDR methylation analysis; remaining cells were 
cultured for 7 days on anti-CD3 and anti-CD28-coated plates in the presence of IL-2 
before analysis of the TSDR region. (A) Unsorted CD4+ T-cells and day 0 sorted 
Treg and Tconv were stained for FOXP3. Flow cytometry plots display CD25 and 
FOXP3 expression in the three populations and histograms display the FOXP3 and 
CD25 expression levels (black=Tconv; red=Treg). (B) Following 7 days of culture, 
Tconv cells were harvested and stained for CD4, CD25 and FOXP3, before sorting 
in to CD25hiFOXP3hi and CD25hiFOXP3lo subsets. Flow cytometry plots displaying 
CD25 vs. FOXP3 expression, and histograms displaying FOXP3 or CD25 levels in 
the sorted subsets (CD25hiFOXP3hi=red; CD25hiFOXP3lo=blue). (C) DNA extracted 
from Treg and Tconv at day 0 and activated Tconv at day 7 was bisulfite treated, 
the TSDR region amplified, cloned and sequenced to determine the methylation 
status. Displayed are the heat maps of the methylation levels of 15 CpG positions, 
plus region average, in intron 1 of the FOXP3 gene in the four populations. One of 
two independent experiments is shown. 
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Supplementary Figure 3: P3 Treg show a small enrichment for IL-2 and IL-
17A-producing cells but express comparable levels of the Latency-Associated 
Peptide (LAP). 
(A) Purity of enriched P2 and P3 Treg populations used in Figure 5, based on CD25 
and FOXP3 expression, n=6. (B) SFMC were stimulated for 2hrs with PMA and 
Ionomycin in the presence of Brefeldin A before staining for CD3, CD4, CD127, 
CD25, FOXP3, IL-2 and IL-17A. The frequency of IL-2 and IL-17A positive cells 
within the three Treg subsets was then determined, n=4 (C) SFMC were stained for 
CD3, CD4, CD127, CD25, FOXP3 and LAP and the expression of LAP quantified 
for each Treg subset. MFI = Median Fluorescence Intensity, n=4. 
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